Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Here’s Why

Oculis Holding AG (NASDAQ:OCS) shares saw unusually-strong trading volume on Monday . Approximately 547,574 shares changed hands during mid-day trading, an increase of 12% from the previous session’s volume of 488,176 shares.The stock last traded at $10.7160 and had previously closed at $11.21.

Analyst Ratings Changes

A number of analysts have recently issued reports on OCS shares. HC Wainwright lowered their price target on Oculis from $47.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Tuesday, April 21st. JPMorgan Chase & Co. lowered their price target on Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Needham & Company LLC lowered their price target on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Finally, Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.33.

Oculis Stock Performance

The stock has a market cap of $613.60 million, a PE ratio of -4.97 and a beta of 0.23. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average of $26.45 and a 200 day moving average of $24.98.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. Equities analysts predict that Oculis Holding AG will post -2.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gildi lifeyrissjodur acquired a new stake in Oculis during the fourth quarter worth $50,250,000. Aberdeen Group plc increased its stake in Oculis by 39.4% during the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock worth $34,887,000 after acquiring an additional 493,827 shares during the last quarter. Syquant Capital Sas acquired a new stake in Oculis during the fourth quarter worth $3,849,000. Simplify Asset Management Inc. purchased a new position in shares of Oculis during the 4th quarter worth approximately $1,972,000. Finally, Propel Bio Management LLC purchased a new position in shares of Oculis during the 4th quarter worth approximately $3,452,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.